pyrimethamine has been researched along with Tay-Sachs Disease in 2 studies
Maloprim: contains above 2 cpds
Tay-Sachs Disease: An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrimethamine (PMT) was previously shown to act as a HexA chaperone in human fibroblasts in vitro carrying some (e." | 2.80 | Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study. ( Elstein, D; Fattal-Valevski, A; Lerman-Sagie, T; Navon, R; Osher, E; Peleg, L; Sagie, L; Sagiv, N; Stern, N; Urshanski, N; Valevski, A; Zimran, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osher, E | 2 |
| Fattal-Valevski, A | 2 |
| Sagie, L | 2 |
| Urshanski, N | 2 |
| Sagiv, N | 1 |
| Peleg, L | 2 |
| Lerman-Sagie, T | 2 |
| Zimran, A | 2 |
| Elstein, D | 2 |
| Navon, R | 2 |
| Valevski, A | 2 |
| Stern, N | 2 |
| Amir-Levi, Y | 1 |
| Katzburg, S | 1 |
2 trials available for pyrimethamine and Tay-Sachs Disease
| Article | Year |
|---|---|
Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation, E | 2015 |
Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay Sachs.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Enzyme Activation; Female; Folic A | 2011 |